Evidence mapPaperPMID 39086991Full record

ArticleTherapeutic advances in gastroenterology2024

DOMINO trial

Claudia Di Rosa, Karen Van den Houte, Annamaria Altomare, Michele Pier Luca Guarino, Linde Besard, Joris Arts, Philip Caenepeel, Hubert Piessevaux, Alain Vandenberghe, Cristophe Matthys and 17 more

Registry-linked trialAbstract read
In one paragraph

Article in Therapeutic advances in gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04270487 (A Randomized Controlled Trial to Evaluate the Short-term Efficacy and Long-term Health Economic Impact of a Dietary Intervention Compared to Pharmacotherapy With a Musculotropic Spasmolytic Agent for Newly Diagnosed or Newly Treated Irritable Bowel Syndrome in Primary Care), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04270487 phase4completednot on this map

A Randomized Controlled Trial to Evaluate the Short-term Efficacy and Long-term Health Economic Impact of a Dietary Intervention Compared to Pharmacotherapy With a Musculotropic Spasmolytic Agent for Newly Diagnosed or Newly Treated Irritable Bowel Syndrome in Primary Care

TypeinterventionalSponsorUniversitaire Ziekenhuizen KU LeuvenRan2018 to 2020Enrolled472ConditionsIrritable Bowel SyndromeArmsIBS Diet, Otilonium Bromide
3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Claudia Di RosaCampus Bio-Medico University, Roma, Italy.
Karen Van den HouteTranslational Research Center for Gastrointestinal Diseases (TARGID), Department of Chronic Diseases and Metabolism (ChroMeta), University of Leuven, Leuven, Belgium.
Annamaria AltomareCampus Bio-Medico University, Roma, Italy.
Michele Pier Luca GuarinoCampus Bio-Medico University, Roma, Italy.
Linde BesardDepartment of Gastroenterology, University Hospital Leuven (UZ Leuven), Leuven, Belgium.
Joris ArtsDepartment of Gastroenterology, Algemeen Ziekenhuis Sint Lucas, Brugge, Belgium.
Philip CaenepeelHosptial Oost-Limburg, Genk, Belgium.
Hubert PiessevauxDepartment of Gastroenterology and Hepatology, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium.
Alain VandenbergheBVBA, Chaumont-Gistoux, Belgium.
Cristophe MatthysClinical and Experimental Endocrinology, Departments of Chronic Diseases and Metabolism, and Endocrinology, University Hospitals Leuven, Leuven, Belgium.
Jessica R BiesiekierskiTranslational Research Center for Gastrointestinal Diseases (TARGID), Department of Chronic Diseases and Metabolism (ChroMeta), University of Leuven, Leuven, Belgium.
Luc CapiauGeneral Medicine Practice, Massemen, Belgium.
Steven CeulemansGeneral Medicine Practice, Beverst, Belgium.
Olivier GernayGeneral Medicine Practice, Gent, Belgium.
Lydia JonesGeneral Medicine Practice, Rixensart, Belgium.
Sophie MaesGeneral Medicine Practice, Leuven, Belgium.
Christian PeetermansGeneral Medicine Practice, Haacht, Belgium.
Willem RaatDepartment of Public Health and Primary Care, KU Leuven, Leuven, Belgium.
Jeroen StubbeGeneral Medicine Practice, Oostende, Belgium.
Rudy Van BoxstaelGeneral Medicine Practice, Betekom, Belgium.
Olivia VandeputGeneral Medicine Practice, Tremelo, Belgium.
Sophie Van SteenbergenGeneral Medicine Practice, Berchem, Belgium.
Lukas Van OudenhoveTranslational Research Center for Gastrointestinal Diseases (TARGID), Department of Chronic Diseases and Metabolism (ChroMeta), University of Leuven, Leuven, Belgium.
Tim VanuytselTranslational Research Center for Gastrointestinal Diseases (TARGID), Department of Chronic Diseases and Metabolism (ChroMeta), University of Leuven, Leuven, Belgium.
Mike JonesFaculty of Human Sciences, Macquarie University, Sydney, NSW, Australia.
Jan TackTranslational Research Center for Gastrointestinal Diseases (TARGID), University Hospital Gasthuisberg, O&N I - Bus 701, Herestraat 49, Leuven B-3000, Belgium.ORCID https://orcid.org/0000-0002-3206-6704
Florencia CarboneTranslational Research Center for Gastrointestinal Diseases (TARGID), Department of Chronic Diseases and Metabolism (ChroMeta), University of Leuven, Leuven, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction characterized by recurrent abdominal pain related to defecation and/or associated to a change in bowel habits. According to the stool type, four different IBS subtypes can be recognized, constipation predominant (IBS-C), diarrhea predominant (IBS-D), mixed (IBS-M), and undefined (IBS-U). Patients report that their IBS symptoms are exacerbated by food. Thus, it is important to find a nutritional approach that could be effective in reducing IBS symptoms. Objective: The present work is a Design: Methods: Two hundred twenty-two primary care IBS patients followed a FODMAP-lowering diet for 8 weeks with the support of a smartphone application. Two follow-up visits were scheduled after 16 and 24 weeks. IBS-Symptoms Severity Score (IBS-SSS), quality of life (QoL), and adherence and dietary satisfaction were evaluated. Results: After 8 weeks, IBS-SSS improved in all IBS subtypes ( Conclusion: This Trial registration: Ethical Commission University Hospital of Leuven reference number: S59482. Clinicaltrial.gov reference number: NCT04270487.

Indexed as

dietary treatment in IBSFODMAP dietIBS subtypes

Identifiers

PMID39086991
PMCPMC11289810

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.